ReviewJournal of medicine and life2022
Triple-negative breast cancer: current treatment strategies and factors of negative prognosis.
Review in Journal of medicine and life, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 1 synthesis or guideline pooled it, 159 citations in OpenAlex.
- Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Pooled it
- Performance of MRI-based deep learning models in differentiation of triple negative breast cancer from other breast cancer subtypes: A systematic review and meta-analysis.European journal of radiology open · 2026Article
- The Prognostic Role of Vimentin Expression in Triple-Negative Breast Cancer: A Retrospective Cohort Study.Cancer reports (Hoboken, N.J.) · 2026Article
- IntratumoralACS omega · 2026Article
- Cepharanthine inhibits lysosomes and induces apoptosis in triple‑negative breast cancer cells.Molecular medicine reports · 2026Article
- Exploration of the multi-component, multi-target, and multi-pathway mechanism ofBiochemistry and biophysics reports · 2026Article
- Evaluation of cytotoxic and cellular effects of zinc nanoparticles from Saccharum officinarum (Jaggery) extract on breast cancer cells.Scientific reports · 2026Article
- Exploring the Molecular and Genomic Landscape of the Dark Agouti Rat Mammary Adenocarcinoma: Preliminary Insights for Triple-Negative Breast Cancer Modeling.Journal of mammary gland biology and neoplasia · 2026Article
- Investigation of Radiolabeled KISS1R Ligands as Promising Tools for Diagnosis and Treatment of Triple-Negative Breast Cancer.Molecular pharmaceutics · 2026Article
- Clinical Outcomes and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A Real-World Data Analysis.World journal of oncology · 2026Article
- Deubiquitination and stabilization of EIF4A3 by OTUB2 contributes to TPI1-mediated glycolysis and TNBC progression.Breast cancer research : BCR · 2026Article
- Association of lncRNA AGAP11 with prognosis and malignant progression in triple-negative breast cancer.Discover oncology · 2026Article
- Evaluating distant recurrence-free survival and location of metastasis in HER2+ breast cancer by ER status.International journal of cancer · 2026Article
- DUSP1: Triple-Negative Breast Cancer and Therapeutic Potential.Current oncology (Toronto, Ont.) · 2026Review
- Synergistic combination of pirfenidone and paclitaxel suppresses migration and stemness in triple-negative breast cancer: implications of EMT and pluripotency pathways.BMC pharmacology & toxicology · 2026Article
- Harnessing albumin's natural tumor-targeting properties: nanoplatform strategies for triple-negative breast cancer therapy.Discover nano · 2026Review
- Subtype-Specific mInternational journal of molecular sciences · 2026Article
- Datopotamab deruxtecan in Chinese patients with heavily pretreated advanced or metastatic triple-negative breast cancer in the phase I/II TROPION-PanTumor02 study.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Article
- Synthesis and anti-cancer activity of naphthalimide-organylselanyl conjugates.Beilstein journal of organic chemistry · 2026Article
- Signalling Pathways and Inhibitors in Triple Negative Breast Cancer: Current Progress.Anti-cancer agents in medicinal chemistry · 2026Review
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common cancer in women and the most common cause of death in working-age women. According to the results of immunohistochemical studies, 10-20% of cases revealed a triple-negative type of breast cancer. This subtype is characterized by significant proliferative activity and growth rate, aggressive clinical course, and early metastasis. This leads to a suspicious prognosis and, accordingly, encourages an increase of surgical treatment radicalism and aggressive systemic treatment. This review briefly analyzes existing treatment strategies for triple-negative breast cancer with a focus on surgical treatment. Surgical treatment is an integral part of complex therapy. Currently, the attention of researchers is focused not only on the radicalism of the operation, ensuring long-term survival, but also on achieving a good cosmetic result that determines the quality of life of patients. In this aspect, organ-preserving and prosthetic methods of operations are promising, the feasibility and effectiveness of which are being discussed. The relevance of choosing the optimal method of operation is evidenced by the lack of generally accepted approaches based on informative markers for the prognosis of the course of the disease. Therefore, the choice of the optimal method of surgical treatment taking into account the individual characteristics of the patient and the tumor, indications for chemotherapy, and radiation therapy remains an unresolved issue and requires further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.